XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share
9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The following table sets forth the calculation of basic and diluted earnings per share:

 BasicDiluted
 Third Quarter
 2020201920202019
($ in millions, except per share amounts,
shares in millions)
Net income$569 $657 $569 $657 
Dividend equivalent payments(2)(1)(1)— 
Income available to common stockholders$567 $656 $568 $657 
Weighted-average shares outstanding254.6 262.1 254.6 262.1 
    
Dilutive effect of outstanding options and share-settled awards  1.5 2.2 
Adjusted weighted-average shares outstanding  256.1 264.3 
Earnings per share$2.23 $2.50 $2.22 $2.49 
 BasicDiluted
 First Nine Months
 2020201920202019
($ in millions, except per share amounts,
shares in millions)
Net income$1,342 $2,056 $1,342 $2,056 
Dividend equivalent payments(3)(4)(2)— 
Income available to common stockholders$1,339 $2,052 $1,340 $2,056 
Weighted-average shares outstanding255.7 264.6 255.7 264.6 
    
Dilutive effect of outstanding options and share-settled awards  1.5 2.3 
Adjusted weighted-average shares outstanding 257.2 266.9 
Earnings per share$5.24 $7.76 $5.21 $7.70 
During the third quarters and first nine months of 2020 and 2019, we made dividend equivalent payments to certain holders of stock options and RSUs.  For purposes of computing basic earnings per share, dividend equivalent payments made to holders of stock options and RSUs were deducted from net income to determine income available to common stockholders. For purposes of computing diluted earnings per share, we evaluate on a grant-by-grant basis those stock options and RSUs receiving dividend equivalent payments under the two-class and treasury stock methods to determine which method is more dilutive for each grant. For those grants for which the two-class method was more dilutive, net income was reduced by dividend equivalent payments to determine income available to common stockholders. There are no awards outstanding that were antidilutive for the third quarters and first nine months ended September 30, 2020 and 2019.